This session is not CME/CMLE eligible
Description
This session will focus on clonal but not overtly malignant processes of diagnostic relevance in hematopathology. Speakers will focus on a newly described hematologic/rheumatologic disease, VEXAS, along with paroxysmal nocturnal hemoglobinuria and aplastic anemia. The underlying genetic basis and molecular testing considerations in these diseases will be emphasized. In addition, the relationship of these diseases to overt myeloid malignancy will be explored.
Learning Objectives
- Upon completion, participants will be able to describe key clinicopathologic features of VEXAS, PNH, and aplastic anemia.
- Upon completion, participants will be able to define molecular features of VEXAS, PNH, and aplastic anemia.
- Upon completion, participants will be able to discuss clonal evolution of aplastic anemia and describe its relationship to overt myeloid neoplasia..
Neal Stuart Young, MD
NHLBI, Bethesda, Maryland, United States 
Daria Babushok, MD PhD
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Continuing Education Credit:
Duration: 1.5
Recording Date: November 17, 2023
CME/CMLE credit: 1.5 hr
Last day to claim CME/CMLE: December 31, 2026
